Panel rules on second blood cancer drug case

Panel rules on second blood cancer drug case

An ICC tribunal has issued a partial award in a second arbitration between a Taiwanese pharmaceutical company and its Austrian partner over a blood cancer treatment – a case where the parties had been seeking US$5 billion.  

Unlock unlimited access to all Global Arbitration Review content